Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Psychiatric Clinics of North America

• Publication date

  1993-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0193-953X(18)30166-7PMID 8105453
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An experimental model of tardive dyskinesia

  2005cited by this paper
• Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys

  2005cited by this paper
• Clozapine: neuroleptic-induced EPS and tardive dyskinesia

  2004cited by this paper
• D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics

  2004cited by this paper
• Acute extrapyramidal side effects: Serum levels of neuroleptics and anticholinergics

  2004cited by this paper
• Neuroleptic-induced akathisia: a review

  2004cited by this paper
• Acute dystonia induced by neuroleptic drugs

  2004cited by this paper
• Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects

  2004cited by this paper
• Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study.

  1992cited by this paper
• Treatment of tardive dyskinesia with vitamin E.

  1992cited by this paper
• Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.

  1991cited by this paper
• Prevalence and severity of akathisia in patients on clozapine.

  1991cited by this paper
• Prospective study of tardive dyskinesia incidence in the elderly.

  1991cited by this paper
• Computed tomographic evaluation of patients with tardive dyskinesia.

  1991cited by this paper
• Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects.

  1991cited by this paper
• Tardive dyskinesia.

  1990cited by this paper
• Clozapine effects on tardive dyskinesia.

  1989cited by this paper
• Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.

  1989cited by this paper
• Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.

  1988cited by this paper
• Clinical forms of severe tardive dyskinesia.

  1987cited by this paper
• Prediction of Neuroleptic‐Induced Dystonia

  1987cited by this paper
• Alpha-tocopherol in tardive dyskinesia.

  1987cited by this paper
• Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study.

  1986cited by this paper
• Spontaneous and tardive dyskinesias: clinical and laboratory studies.

  1985cited by this paper
• Akathisia variants and tardive dyskinesia.

  1985cited by this paper
• Tardive dyskinesia in the aged. Duration of treatment relationships.

  1985cited by this paper
• Propranolol in the treatment of neuroleptic-induced akathisia.

  1984cited by this paper
• Tardive dyskinesia--animal models.

  1984cited by this paper
• Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents.

  1984cited by this paper
• Incidence of tardive dyskinesia: five-year data from a prospective study.

  1984cited by this paper
• Prevalence of tardive dyskinesia in elderly samples.

  1984cited by this paper
• Blepharospasm and orofacial‐cervical dystonia: Clinical and pharmacological findings in 100 patients

  1983cited by this paper
• Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes.

  1983cited by this paper
• Tardive dyskinesia: a 3-year follow-up study

  1983cited by this paper
• Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment.

  1983cited by this paper
• Neuroleptic-induced dyskinesias in children.

  1983cited by this paper
• Serum Concentration of Depot Neuroleptics in Tardive Dyskinesia

  1983cited by this paper
• The coexistence of parkinsonism-like symptoms and tardive dyskinesia.

  1982cited by this paper
• Tardive dyskinesia: prevalence and risk factors, 1959 to 1979

  1982cited by this paper
• Research diagnoses for tardive dyskinesia.

  1982cited by this paper
• Tardive dystonia

  1982cited by this paper
• Therapeutic strategies against tardive dyskinesia. Two decades of experience.

  1982cited by this paper
• A biochemical study of tardive dyskinesia in young male patients.

  1981cited by this paper
• The differential diagnosis of tardive dyskinesia

  1981cited by this paper
• Changes in prevalence, severity, and recovery in tardive dyskinesia with age.

  1980cited by this paper
• Changes in dopamine-mediated behaviour during one year's neuroleptic administration.

  1979cited by this paper
• Tardive Dyskinesia and Dementia

  1979cited by this paper
• Tardive dyskinesia--reversible and persistent.

  1979cited by this paper
• Tardive dyskinesia: are first signs reversible?

  1977cited by this paper
• Pharmacological characterization of tardive dyskinesia

  1977cited by this paper
• Haloperidol-induced tardive dyskinesia in monkeys

  1976cited by this paper
• Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects

  1976cited by this paper
• On the supersensitivity of dopamine receptors, induced by neuroleptics

  1976cited by this paper
• Dystonic reactions following neuroleptics: Time Course and proposed mechanisms

  1976cited by this paper
• Tardive dyskinesia and depressive illness.

  1976cited by this paper
• Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects.

  1974cited by this paper
• Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia

  1974cited by this paper
• Pharmacologically induced behavioural supersensitivity to apomorphine.

  1973cited by this paper
• Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system.

  1971cited by this paper
• NEUROLOGICAL SYMPTOMS IN PHARMACOTHERAPY OF PSYCHOSES.

  1964cited by this paper
• A survey of drug-induced extrapyramidal reactions.

  1961cited by this paper

• Novel Multimodal Salicylamide Derivative with Antidepressant-like, Anxiolytic-like, Antipsychotic-like, and Anti-Amnesic Activity in Mice

  2023cites this paper
• Presbyphagia and dysphagia in old age

  2020cites this paper
• Sex-based pharmacotherapy in acute care setting, a narrative review for emergency providers.

  2020cites this paper
• A pharmacological profile of intravenous amisulpride for the treatment of postoperative nausea and vomiting

  2020cites this paper
• A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults

  2019cites this paper
• A meta-analysis of peripheral blood nerve growth factor levels in patients with schizophrenia

  2017cites this paper
• Electroconvulsive Therapy: Solution or a Cause of Tardive Dyskinesia?

  2017cites this paper
• Association between DBH 19bp insertion/deletion polymorphism and cognition in schizophrenia with and without tardive dyskinesia.

  2017cites this paper
• Employing proteomics to unravel the molecular effects of antipsychotics and their role in schizophrenia

  2016cites this paper
• Comparison of Risperidon & Olanzapine for Extrapyramidal Side Effects on Schizophrenic Patients in Haryana, India

  2014cites this paper
• The usefulness of non-human primates in central nervous system safety pharmacology.

  2013cites this paper
• Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers.

  2013cites this paper
• Prunella vulgaris Attenuates Prepulse Inhibition Deficit and Attention Disruption induced by MK‐801 in Mice

  2013cites this paper
• The Association Study of Polymorphisms in DAT, DRD2, and COMT Genes and Acute Extrapyramidal Adverse Effects in Male Schizophrenic Patients Treated With Haloperidol

  2013cites this paper
• Metody badania spontanicznych i spowodowanych lekami przeciwpsychotycznymi zaburzeń ruchowych w schizofrenii

  2013cites this paper
• Relevance of animal models to human tardive dyskinesia

  2012cites this paper
• A Case Report of Citalopram Induced Acute Mandibular Dystonia

  2012cites this paper
• Psychiatric and neurological symptoms in schizophrenia and substance use disorder patients treated for 12-weeks with quetiapine

  2012cites this paper
• Neuroleptic-Induced Movement Disorders: Past and Present

  2012cites this paper
• schizophrenia. A study using instrumental measures Tardive dyskinesia and positive and negative symptoms of

  2011cites this paper
• Vascular chorea in adults and children.

  2011cites this paper
• Akathisia after mild traumatic head injury.

  2010cites this paper
• JPET #166710 PIP BEHAVIORAL INDICES IN ANTIPSYCHOTIC DRUG DISCOVERY

  2010influential citation
• Discinesia tardía inducida por neurolépticos. A propósito de un caso

  2010cites this paper
• Behavioral Indices in Antipsychotic Drug Discovery

  2010influential citation
• Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature

  2010cites this paper
• Quetiapine-associated dysphagia

  2009cites this paper
• Letters to the Editor

  2009cites this paper
• Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis.

  2009cites this paper
• Tachyphylaxis after Repeated Antidepressant Drug Exposure in Patients with Recurrent Major Depressive Disorder

  2009cites this paper
• Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.

  2009cites this paper
• Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?

  2009cites this paper
• Preclinical behavioral models for predicting antipsychotic activity.

  2009cites this paper
• Preliminary communication Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode

  2008cites this paper
• Do we need another atypical antipsychotic?

  2008cites this paper
• Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

  2008cites this paper
• Physical illness and schizophrenia: a review of the literature

  2007cites this paper
• مورد نادر Oculogyric Crisis ناشی از کلوزاپین

  2007cites this paper
• Chronic restlessness with antipsychotics.

  2007cites this paper
• The course and outcome of psychiatric illness in people with Prader-Willi syndrome: implications for management and treatment.

  2007cites this paper
• Antipsikotik Kullanýmýna Baðlý Aðýz ve Yüz Bölgesinde Geliþen Distoni ile Ýlgili Temporomandibuler Eklem Çýkýðý: Bir Olgu Sunumu

  2007cites this paper
• Factors related to antipsychotic oversupply among Central Texas Veterans.

  2007cites this paper
• Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment

  2006cites this paper
• Methylphenidate-induced akathisia in a patient with multiple sclerosis.

  2006cites this paper
• Evidence for instrument and family-specific variation of subclinical psychosis dimensions in the general population.

  2006cites this paper
• Antipsychotic drug utilization patterns and treatment -emergent diabetes: A methodological comparison of incidence using a claims database

  2006cites this paper
• Effectiveness of olanzapine for systemic lupus erythematosus-related psychosis.

  2006cites this paper
• Combined Effects of Itraconazole and CYP2D6*10 Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Haloperidol in Healthy Subjects

  2006cites this paper
• Acute Dystonic Reaction and the Neuroleptic Malignant Syndrome

  2005influential citation
• Gender Differences in Pharmacokinetics and Side Effects of Second Generation Antipsychotic Drugs

  2005cites this paper
• CHAPTER M2 – Neuroleptic-Induced Acute Dystonia and Tardive Dyskinesia in Primates

  2005cites this paper
• Olanzapine vs haloperidol for treatment of schizophrenia.

  2004cites this paper
• The AMUP study for drug surveillance in psychiatry - a summary of inpatient data.

  2004cites this paper
• The AMÜP Study for Drug Surveillance in Psychiatry - a Summary of Inpatient Data

  2004cites this paper
• Olanzapine vs haloperidol for treatment of schizophrenia.

  2004cites this paper
• Pathophysiology of antipsychotic drug-induced movement disorders.

  2004cites this paper
• Assessing and Monitoring Antipsychotic-Induced Movement Disorders in Hospitalized Patients: A Cautionary Study

  2004cites this paper
• Katatonie — 130 Jahre nach Karl Ludwig Kahlbaum

  2004cites this paper
• Unusual phenotypes in DYT1 dystonia: A report of five cases and a review of the literature

  2003cites this paper
• The causes of underdiagnosing akathisia.

  2003cites this paper
• Olanzapine and fluoxetine combination in severe or resistant depression

  2003cites this paper
• Tetrabenazine in the treatment of severe pediatric chorea

  2003cites this paper
• Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake.

  2003cites this paper
• Neuroleptic-induced akathisia and violence: a review.

  2003cites this paper
• [Acute pharmacological extrapyramidal disturbances].

  2003cites this paper
• Chapter 127 – Tardive Dyskinesia and Other Drug-Related Movement Disorders

  2003cites this paper
• The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment

  2002cites this paper
• The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders

  2002cites this paper
• Swallowing Disorders in the Elderly

  2002cites this paper
• Neuroleptic drug exposure and incidence of tardive dyskinesia: a records-based case-control study.

  2002cites this paper
• Movement Disorders Induced by Dopamine Blocking Agents

  2001cites this paper
• Movement disorders associated with neuroleptic treatment.

  2001cites this paper
• Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia.

  2001cites this paper
• Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.

  2001cites this paper
• Risk factors for tardive dyskinesia in a large population of youths and adults.

  2001cites this paper
• A novel augmentation strategy for treating resistant major depression.

  2001cites this paper
• Tardive dyskinesia: pathophysiology and animal models.

  2000cites this paper
• The new generation of antipsychotic drugs: how atypical are they?

  2000cites this paper
• Pharmacist‐Designed and ‐Implemented Pharmaceutical Care Plan for Antipsychotic‐Induced Movement Disorders

  2000cites this paper
• L-prolyl-l-leucyl-glycinamide and its peptidomimetic analog 3(R)-[(2(S)-pyrrolidylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) attenuate haloperidol-induced c-fos expression in the striatum.

  2000cites this paper
• Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia

  2000cites this paper
• A Computational Model of Information Processing in the Frontal Cortex and Basal Ganglia

  2000cites this paper
• General Overview of Contemporary Antipsychotic Medications

  2000cites this paper
• Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution.

  1999cites this paper
• Motor deficits and schizophrenia: the evidence from neuroleptic-naïve patients and populations at risk.

  1999cites this paper
• Atypical Antipsychotics Part I: Pharmacology, Pharmacokinetics, and Efficacy

  1999cites this paper
• Nithsdale Schizophrenia Surveys 17

  1998cites this paper
• Marked reduction of tardive dyskinesia with olanzapine.

  1998cites this paper
• Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat.

  1998cites this paper
• Treatment of schizophrenia in childhood and adolescence.

  1998cites this paper
• 8. Psychoses: a primary care perspective

  1998cites this paper
• Persistent loss of tyrosine hydroxylase immunoreactivity in the substantia nigra after neuroleptic withdrawal

  1998cites this paper
• Assessment and Management of Antipsychotic-Induced Adverse Events

  1998cites this paper
• [Follow up of a schizophrenic patient in general practice].

  1998cites this paper
• Neuroleptiques

  1997cites this paper
• The relationship of pharmacology to side effects.

  1997cites this paper
• Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.

  1997cites this paper
• Atypical Antipsychotics and the Pharmacology of Olanzapine

  1997cites this paper
• New strategies for old problems: tardive dyskinesia (TD). Review and report on severe TD cases treated with clozapine, with 12, 8 and 5 years of video follow-up.

  1997cites this paper
• Movement disorders associated with withdrawal from high-dose intravenous haloperidol therapy in delirious ICU patients.

  1997cites this paper